Literature DB >> 9462239

Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

A A Brink1, D F Dukers, A J van den Brule, J J Oudejans, J M Middeldorp, C J Meijer, M Jiwa.   

Abstract

AIMS: To investigate the expression pattern of Epstein-Barr virus (EBV) latent genes at the single cell level in post-transplantation lymphoproliferative disorders and acquired immunodefiency syndrome (AIDS) related lymphomas, in relation to cellular morphology.
METHODS: Nine post-transplantation lymphoproliferative disorders and three AIDS related lymphomas were subjected to immunohistochemistry using monoclonal antibodies specific for EBV nuclear antigen 1 (EBNA1) (2H4), EBNA2 (PE2 and the new rat anti-EBNA2 monoclonal antibodies 1E6, R3, and 3E9), and LMP1 (CS1-4 and S12). Double staining was performed combining R3 or 3E9 with S12.
RESULTS: R3 and 3E9 anti-EBNA2 monoclonal antibodies were more sensitive than PE2, enabling the detection of more EBNA2 positive lymphoma cells. Both in post-transplantation lymphoproliferative disorders and AIDS related lymphomas, different expression patterns were detected at the single cell level. Smaller neoplastic cells were positive for EBNA2 but negative for LMP1. Larger and more blastic neoplastic cells, sometimes resembling Reed-Sternberg cells, were LMP1 positive but EBNA2 negative (EBV latency type II). Morphologically intermediate neoplastic cells coexpressing EBNA2 and LMP1 (EBV latency type III), were detected using R3 and 3E9, and formed a considerable part of the neoplastic population in four of nine post-transplantation lymphoproliferative disorders and two of three AIDS related lymphomas. All samples contained a subpopulation of small tumour cells positive exclusively for Epstein-Barr early RNA and EBNA1. The relation between cellular morphology and EBV expression patterns in this study was less pronounced in AIDS related lymphomas than in post-transplantation lymphoproliferative disorders, because the AIDS related lymphomas were less polymorphic than the post-transplantation lymphoproliferative disorders.
CONCLUSIONS: In post-transplantation lymphoproliferative disorders and AIDS related lymphomas, EBV latency type III can be detected by immunohistochemistry in a subpopulation of tumour cells using sensitive monoclonal antibodies R3 and 3E9. Our data suggest that EBV infected tumour cells in these lymphomas undergo gradual changes in the expression of EBV latent genes, and that these changes are associated with changes in cellular morphology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462239      PMCID: PMC500314          DOI: 10.1136/jcp.50.11.911

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B).

Authors:  E Kremmer; B R Kranz; A Hille; K Klein; M Eulitz; G Hoffmann-Fezer; W Feiden; K Herrmann; H J Delecluse; G Delsol; G W Bornkamm; N Mueller-Lantzsch; F A Grässert
Journal:  Virology       Date:  1995-04-01       Impact factor: 3.616

2.  EBV latent membrane protein (LMP-1) and bcl-2 protein expression in Reed-Sternberg-like cells in post-transplant lymphoproliferative disorders.

Authors:  R Chetty; S C Biddolph; L Kaklamanis; N Cary; S Stewart; A Giatromanolaki; K C Gatter
Journal:  Histopathology       Date:  1996-03       Impact factor: 5.087

3.  Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells.

Authors:  P Kanavaros; J Briere; M C Lescs; P Gaulard
Journal:  J Pathol       Date:  1996-03       Impact factor: 7.996

4.  Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders.

Authors:  J J Oudejans; M Jiwa; A J van den Brule; F A Grässer; A Horstman; W Vos; P M Kluin; P van der Valk; J M Walboomers; C J Meijer
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

5.  Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.

Authors:  F A Grässer; P G Murray; E Kremmer; K Klein; K Remberger; W Feiden; G Reynolds; G Niedobitek; L S Young; N Mueller-Lantzsch
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

6.  Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.

Authors:  D Rea; C Fourcade; V Leblond; M Rowe; I Joab; L Edelman; M O Bitker; I Gandjbakhch; C Suberbielle; J P Farcet
Journal:  Transplantation       Date:  1994-08-15       Impact factor: 4.939

7.  Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clinical, virological, and immunopathological studies.

Authors:  D T Purtilo; K Sakamoto; A K Saemundsen; J L Sullivan; A C Synnerholm; M Anvret; J Pritchard; C Sloper; C Sieff; J Pincott; L Pachman; K Rich; F Cruzi; J A Cornet; R Collins; N Barnes; J Knight; B Sandstedt; G Klein
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes.

Authors:  J J Oudejans; A J van den Brule; N M Jiwa; P C de Bruin; G J Ossenkoppele; P van der Valk; J M Walboomers; C J Meijer
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.

Authors:  A Carbone; R Dolcetti; A Gloghini; R Maestro; E Vaccher; D di Luca; U Tirelli; M Boiocchi
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

10.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  22 in total

Review 1.  Molecular diagnosis of Epstein-Barr virus-related diseases.

Authors:  M L Gulley
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

2.  CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma.

Authors:  J P Christensen; R D Cardin; K C Branum; P C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Cervical cancer.

Authors:  P J van Diest; H Holzel
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

4.  Non-Hodgkin's lymphoma manifest as gingival hyperplasia in a renal transplant recipient.

Authors:  Jung Hyun Kwon; Joon Chang Song; Sang Hun Lee; So Young Lee; Chul Woo Yang; Yong Soo Kim; Byung Kee Bang
Journal:  Korean J Intern Med       Date:  2005-12       Impact factor: 2.884

Review 5.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

6.  Epstein-Barr virus infection of human astrocyte cell lines.

Authors:  A Menet; C Speth; C Larcher; W M Prodinger; M G Schwendinger; P Chan; M Jäger; F Schwarzmann; H Recheis; M Fontaine; M P Dierich
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Multicentric primary intestinal EBV-positive diffuse large B cell lymphoma of the elderly presenting with perforation.

Authors:  Shih-Sung Chuang; Ryo Ichinohasama; Chun-Chieh Yang; Wen-Ching Wang; Chung-Kuao Chou; Yung-Liang Liao; Szu-Yin Kuo; Shu-Hui Lin
Journal:  Int J Hematol       Date:  2010-02-13       Impact factor: 2.490

8.  Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.

Authors:  B F Israel; R J Pickles; D M Segal; R D Gerard; S C Kenney
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus.

Authors:  Christoph Mancao; Markus Altmann; Berit Jungnickel; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

10.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.